125 related articles for article (PubMed ID: 18772160)
1. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Michelsen PB
J Antimicrob Chemother; 2008 Dec; 62(6):1285-90. PubMed ID: 18772160
[TBL] [Abstract][Full Text] [Related]
2. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Carlyn CJ; Michelsen PB
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):299-304. PubMed ID: 15893901
[TBL] [Abstract][Full Text] [Related]
3. Time-kill studies with micafungin and voriconazole against Candida glabrata intracellularly in human monocyte-derived macrophages and extracellularly in broth.
Baltch AL; Ritz W; Bopp LH; Michelsen PB; Smith RP
Diagn Microbiol Infect Dis; 2011 Aug; 70(4):468-74. PubMed ID: 21767703
[TBL] [Abstract][Full Text] [Related]
4. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans.
Chiller T; Farrokhshad K; Brummer E; Stevens DA
Med Mycol; 2002 Feb; 40(1):21-6. PubMed ID: 11860010
[TBL] [Abstract][Full Text] [Related]
5. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
Nagappan V; Boikov D; Vazquez JA
Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.
Kiraz N; Dag I; Yamac M; Kiremitci A; Kasifoglu N; Oz Y
Antimicrob Agents Chemother; 2010 May; 54(5):2244-7. PubMed ID: 20194697
[TBL] [Abstract][Full Text] [Related]
8. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.
Bopp LH; Baltch AL; Ritz WJ; Michelsen PB; Smith RP
J Med Microbiol; 2006 Jul; 55(Pt 7):865-870. PubMed ID: 16772413
[TBL] [Abstract][Full Text] [Related]
9. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.
Vora S; Purimetla N; Brummer E; Stevens DA
Antimicrob Agents Chemother; 1998 Apr; 42(4):907-10. PubMed ID: 9559806
[TBL] [Abstract][Full Text] [Related]
10. Effects of anidulafungin and voriconazole, singly and in combination, on cytokine/chemokine production by human monocyte-derived macrophages infected with Candida glabrata or activated by lipopolysaccharide.
Baltch AL; Lawrence D; Ritz WJ; Andersen N; Bopp LH; Michelsen PB; Carlyn CJ; Smith RP
Chemotherapy; 2012; 58(2):146-51. PubMed ID: 22584412
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
Ruan SY; Chu CC; Hsueh PR
Antimicrob Agents Chemother; 2008 Aug; 52(8):2919-22. PubMed ID: 18458136
[TBL] [Abstract][Full Text] [Related]
13. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of Caspofungin combined with Fluconazole on mixed Candida albicans and Candida glabrata biofilm.
Pesee S; Angkananuwat C; Tancharoensukjit S; Muanmai S; Sirivan P; Bubphawas M; Tanarerkchai N
Med Mycol; 2016 May; 54(4):384-93. PubMed ID: 26768371
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
16. In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method.
Yang Q; Liu Z; Wang Y; Xie J; Zhang K; Dong Y; Wang YF
Int J Infect Dis; 2022 Sep; 122():982-990. PubMed ID: 35907476
[TBL] [Abstract][Full Text] [Related]
17. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
[TBL] [Abstract][Full Text] [Related]
18. In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Adams EK; Ashcraft DS; Pankey GA
Am J Med Sci; 2016 Mar; 351(3):265-70. PubMed ID: 26992255
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
Chryssanthou E; Cuenca-Estrella M
J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of antifungal additives in Optisol-GS corneal storage medium.
Layer N; Cevallos V; Maxwell AJ; Hoover C; Keenan JD; Jeng BH
JAMA Ophthalmol; 2014 Jul; 132(7):832-7. PubMed ID: 24789459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
